DayTrading Oct 10 Morning, page-65

HIV/HCV market is too small ... most infections are third world without money for expensive treatments.

The money spinner is HCV ... the range of new treatments leaves BIT way out of the park.

Asaid BIT cannot compete with the big pharmo's like Gilead